Immuno-Oncology Cell Therapy Market Outlook Highlighting Regional Growth Trends and Clinical Pipeline Advancements

InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Immuno-Oncology Cell Therapy Market Therapy Type (CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, Cytokine-induced killer cells, Dendritic cells, Macrophages, and Other Cell Therapies), Major Indication (Head & Neck Cancer, Lung Cancer, Kidney Cancer, Melanoma, Lymphoma, Leukemia, and Others) - Technology Trends, Clinical Trial/Pipeline Analysis, Revenue and Forecast Till 2034."

According to the latest market research research, the global Immuno-oncology cell therapies market size is valued at USD 11.9 Billion in 2024, and it is expected to reach USD 95.3 Billion by the year 2034 recording a promising CAGR of 23.2% from 2025 through 2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1083

The advent of advanced immunotherapies has fundamentally reshaped the oncology landscape, offering innovative strategies for cancer treatment by leveraging the body's immune system to identify, target, and eliminate malignant cells. Immuno-oncology, in particular, seeks to enhance the immune response to inhibit tumor progression, with next-generation immunotherapies poised to drive further growth in the oncology sector. This expansion is underpinned by a robust pipeline of clinical trials and recent regulatory approvals, which underscore their potential as both first-line and adjunctive treatment options.

Among the most significant developments are chimeric antigen receptor T-cell (CAR-T) therapies, which have received regulatory approval and continue to evolve through efforts aimed at expanding therapeutic indications, enhancing safety profiles, and optimizing manufacturing processes for greater scalability and efficiency. The COVID-19 pandemic has further underscored the importance of immune-based interventions, prompting increased investment and accelerating demand for immuno-oncology solutions.

The growth of the immuno-oncology cell therapy market is driven by several key factors, including the shift toward immunotherapeutics over conventional cancer treatments, advancements in bioinformatics, the global cancer burden, and a rising emphasis on personalized medicine.

For example, the American Cancer Society reported approximately 1.8 million new cancer diagnoses and over 600,000 cancer-related fatalities in the United States in 2020. In response, heightened research initiatives, coupled with funding from government health agencies and leading pharmaceutical firms, are fostering innovation within the field.

The integration of advanced bioinformatics tools has further enhanced the efficiency of drug development by streamlining costs and timelines, enabling more precise evaluation of therapeutic candidates. Collectively, these scientific and technological advancements are driving continued research, adoption, and market expansion for novel cancer immunotherapies.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

While the immuno-oncology cell therapy market demonstrates significant growth potential, its expansion is expected to face certain constraints. Key challenges include the high costs of therapy development and administration, stringent regulatory requirements-particularly regarding biomarker validation-and limited reimbursement mechanisms. These factors may impede patient access and slow broader adoption over the forecast period.

From a regional perspective, North America is anticipated to maintain its market leadership, driven by substantial healthcare expenditure, robust public awareness, and advanced medical infrastructure. Europe also holds a significant share, supported by consistent government funding for research and development and a high level of clinical trial activity across the region.

The Asia Pacific region is projected to experience the fastest growth through 2030, fueled by rising cancer prevalence, increasing adoption of bioinformatics in drug development, and enhanced government investment in healthcare infrastructure. Key contributors to this regional growth include China, India, and Japan.

The global immuno-oncology cell therapy market remains highly fragmented, with numerous players actively engaged in clinical development. Several pipeline candidates are expected to achieve regulatory approval in the near term. To strengthen market positions, leading companies are pursuing strategies such as product launches in established markets, geographic expansion, collaborative partnerships, licensing agreements, and mergers and acquisitions.

For example, in January 2021, Novartis (Switzerland) entered into a collaboration with BeiGene, Ltd., securing rights to develop and commercialize tislelizumab outside China. This agreement aims to reinforce Novartis's presence in the growing checkpoint inhibitor segment. Tislelizumab, an anti-PD-1 monoclonal antibody, has been specifically engineered to reduce binding affinity to Fcγ receptors on macrophages, potentially enhancing its therapeutic effectiveness.

The global immuno-oncology cell therapy market covers prominent players like Agios Pharmaceutical, Atara Biotherapeutics, Novartis, Juno Therapeutics, Allogene Therapeutics, Shenzhen BinDeBio Ltd., Kite Pharma, Autolus Limited, China Immunotech Co., Ltd., Bellicum Pharmaceuticals, bluebird bio, CARsgen Therapeutics, Cell Design Labs, Calibr, Carina Biotech, Editas Medicine, Celgene Corporation, Cellectis, Cell Medica, Amgen, Celularity, Celyad, Fortress Bio, Fate Therapeutics, Gilead Sciences, JW Therapeutics, Mustang Bio, Ziopharm, Sorrento Therapeutics, Inc., Medigene, Medisix Therapeutics, Precision Biosciences, Lion TCR, Nanjing Legend Biotech, Posedia Therapeutics, Zelluna Immunotherapy, and others prominent players.

Key Developments:
• In Dec 2021, Novartis unveiled T-ChargeTM, its next-generation CAR-T platform, which will serve as the platform for several new investigational CAR-T cell therapies in the Novartis pipeline. Novartis continues to improve the T-Charge platform, which protects T cell stemness, a crucial attribute linked to therapeutic potential, while also implementing significant process savings.
• In Nov 2021, CARsgen Therapeutics Holdings Limited announced that CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the treatment of gastric/gastroesophageal junction cancer (GC/GEJ), has been granted Priority Medicines (PRIME) eligibility by the European Medicines Agency (EMA).
• In Aug 2021, The U.S. Food and Drug Administration (FDA) has approved Kite's Investigational New Drug (IND) application for KITE-363, the company's first chimeric antigen receptor (CAR) T-cell treatment that targets two antigens, CD19 and CD20. Kite intends to begin a multi-center Phase 1 clinical trial assessing KITE-363 in large B-cell lymphoma with this approval (LBCL).
• In Aug 2019, Celgene and Immatics Biotechnologies will collaborate to explore breakthrough adoptive cell therapies for a variety of diseases. Immatics plans to develop T-Cell Receptor Engineered T-cell Therapy (TCR-T) programmes targeting solid tumour targets found by Immatics' XPRESIDENT technology under the terms of the firms' strategic collaboration and option agreement.
• In Jan 2018, Celgene Corporation (U.S.) acquired Juno Therapeutics, Inc. (U.S.), a company engaged in the development of CAR T and TCR (T cell receptor) therapeutics. This acquisition added a novel scientific platform and scalable manufacturing capabilities to complement Celgene's haematology and oncology leadership.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1083

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Therapy Type
• CAR-T Cells
• N.K. & NKT Cells
• TAA/TSA targeted T Cell
• TCR T Cell
• Cytokine-induced killer cells
• Dendritic cells
• Macrophages
• Other Cell Therapies
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Major Indication
• Head & Neck Cancer
• Lung Cancer
• Kidney Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• Europe
• North America
• Asia Pacific
• Latin America
• Middle East & Africa
Europe Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
North America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Asia Pacific Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
• South Africa
• GCC Countries
• Rest of Middle East & Africa

Why should buy this report:
• To receive a detailed analysis of the prospects for global Immuno-oncology cell therapies market
• To receive clinical trial/pipeline analysis of Immuno-oncology cell therapies market
• To analyze the Immuno-oncology cell therapies market drivers and challenges
• To get information on Immuno-oncology cell therapies market size value (US$ Mn) forecast till 2030
• Mergers & Acquisition, Major Investments, in Immuno-oncology cell therapies market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-immuno-oncology-cell-therapy-market/1083

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.